Get the Stockscreener App
16.48
2.69%
-0.455
After Hours:
16.88
0.395
+2.40%
Uniqure N V stock is traded at $16.48, with a volume of 670.26K.
It is down -2.69% in the last 24 hours and up +15.28% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$16.94
Open:
$16.85
24h Volume:
670.26K
Relative Volume:
0.61
Market Cap:
$904.48M
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-4.2054
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
-8.16%
1M Performance:
+15.28%
6M Performance:
+23.58%
1Y Performance:
+197.56%
1-Day Range:
$16.48
$17.19
1-Week Range:
$16.48
$18.17
52-Week Range:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
16.48 | 959.07M | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Parkman Healthcare Partners LLC Sells 71,167 Shares of uniQure N.V. $QURE - MarketBeat
Huntington’s Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma - Barchart.com
OMERS ADMINISTRATION Corp Takes $152,000 Position in uniQure N.V. $QURE - MarketBeat
Cubist Systematic Strategies LLC Makes New $2.56 Million Investment in uniQure N.V. $QURE - MarketBeat
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure stock maintains Buy rating at H.C. Wainwright on promising Fabry data - Investing.com Nigeria
683 Capital Management LLC Boosts Stock Holdings in uniQure N.V. $QURE - MarketBeat
What does recent volatility data suggest for uniQure N.V.Market Growth Report & Real-Time Volume Analysis - Newser
Nantahala Capital Management LLC Has $29.21 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat
uniQure reports positive initial data for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha
Chart based analysis of uniQure N.V. trendsCEO Change & Daily Entry Point Alerts - Newser
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing - GlobeNewswire
uniQure (QURE) Rating Reaffirmed with $70 Price Target by HC Wai - GuruFocus
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease - Benzinga
UniQure Says Early Data for Fabry Disease Gene Therapy Shows Promise - MarketScreener
Long term hold vs stop loss in uniQure N.V.Weekly Trade Report & High Yield Equity Trading Tips - Newser
uniQure reports positive initial data for Fabry disease gene therapy - Investing.com
208-Fold Enzyme Increase: uniQure's One-Time Gene Therapy Could Replace Weekly Infusions for Fabry Disease - Stock Titan
Is uniQure N.V. stock a top performer YTDJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - 더경남뉴스
Is uniQure N.V. exposed to political riskPortfolio Risk Summary & Smart Allocation Stock Reports - 더경남뉴스
uniQure N.V. stock chart pattern explainedJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Using RSI to spot recovery in uniQure N.V.Index Update & Community Shared Stock Ideas - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Is uniQure N.V. stock overvalued or fairly pricedJuly 2025 Snapshot & Capital Efficient Trade Techniques - خودرو بانک
What indicators show strength in uniQure N.V.2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Understanding uniQure N.V.’s price movementWeekly Earnings Recap & Low Drawdown Trading Techniques - Newser
What’s the RSI of uniQure N.V. stockJuly 2025 Movers & Low Risk Growth Stock Ideas - خودرو بانک
Visual analytics tools that track uniQure N.V. performanceQuarterly Portfolio Review & Weekly High Potential Alerts - Newser
Price action breakdown for uniQure N.V.2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
What technical models suggest about uniQure N.V.’s comebackJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is now a turning point for uniQure N.V.Wall Street Watch & Weekly Top Stock Performers List - Newser
Has uniQure N.V. formed a bullish divergenceJuly 2025 Levels & Precise Buy Zone Identification - Newser
Will a bounce in uniQure N.V. offer an exitMarket Activity Summary & Daily Momentum Trading Reports - Newser
Relative strength of uniQure N.V. in sector analysisJuly 2025 Analyst Calls & Daily Technical Stock Forecast Reports - Newser
Ranking uniQure N.V. among high performing stocks via tools2025 Key Lessons & Consistent Growth Equity Picks - Newser
Can uniQure N.V. rally from current levelsJuly 2025 Price Swings & Accurate Buy Signal Alerts - Newser
Using economic indicators to assess uniQure N.V. potential2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Should I hold or sell uniQure N.V. nowJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - خودرو بانک
Can uniQure N.V. outperform in the next rallyJuly 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
Using data tools to time your uniQure N.V. exitPortfolio Profit Report & Weekly Stock Performance Updates - Newser
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):